Liquidity is under severe pressure as the company continues to burn cash, with free cash flow outflows reaching $298.2K in 2025Q2 despite a lack of commercial revenue.
| Cash from Operations | -1.18M | -1.84M | -55.66K | -3.02M | -688.41K | -253.63K |
| Operating CF Margin % | - | -359.91% | -15.9% | - | - | - |
| Operating CF Growth % | 118.69% | -3200.25% | 98.16% | -339.09% | -171.43% | - |
| Net Income | -2.97M | -1.41M | 13.56K | 3.79M | 8.7M | -2.54M |
| Depreciation & Amortization | 0 | 104.73K | 2.45K | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 26.58K | 4.09K | 0 | 0 | 0 |
| Other Non-Cash Items | 1.6M | 11.24K | 50.94K | -6.11M | -10.02M | 2.19M |
| Working Capital Changes | 196.36K | -567.81K | -126.7K | -697.49K | 632.18K | 90.42K |
| Change in Receivables | 0 | -11.02K | -63.86K | 0 | 0 | 0 |
| Change in Inventory | 0 | 28.52K | -30.57K | 0 | 0 | 0 |
| Change in Payables | 0 | 10.2K | 5.39K | -530.95K | 531.18K | 67.26K |
| Cash from Investing | 7.95M | -2.9M | -290 | 100.38M | -1.15M | -116.72M |
| Capital Expenditures | 0 | -74.91K | -290 | 0 | 0 | 0 |
| CapEx % of Revenue | - | 14.68% | 0.08% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 8.2M | -2.84M | 528.51K | 101.78M | 0 | 0 |
| Cash from Financing | -6.81M | 7.73M | 113.89K | -97.34M | 1.15M | 117.67M |
| Debt Issued (Net) | 1.13M | -32.98K | -32.61K | 4.2M | 1.15M | 0 |
| Equity Issued (Net) | -1.58M | 1000K | 52.95K | -1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -7.94M | 0 | 0 | -101.55M | 0 | 0 |
| Other Financing | 0 | -99.56K | 93.54K | 0 | 0 | 0 |
| Net Change in Cash | -33.66K | 3.05M | 56.96K | 8.73K | -688.41K | 693.82K |
| Free Cash Flow | -1.18M | -4.75M | -55.95K | -3.02M | -688.42K | -253.62K |
| FCF Margin % | - | -930.29% | -15.98% | - | - | - |
| FCF Growth % | - | -8386.27% | 98.15% | -339.08% | -171.44% | - |
| FCF per Share | -0.34 | -1.15 | -0.00 | -0.33 | -0.05 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.40x | 1.30x | -4.10x | -0.80x | -0.08x | 0.10x |
| Interest Paid | 0 | 772 | 2.14K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Critical liquidity and financing
According to the provided financial data, YDES exhibits a persistent disconnect between reported net income and operating cash flow, with the OCF/NI ratio fluctuating between -0.99 and 0.15, suggesting that accounting earnings provide little insight into the actual cash-consuming nature of the company's core diagnostic operations.
The extreme volatility in net income, highlighted by the $17.1M gain in 2024Q2, appears entirely decoupled from the consistent negative operating cash flows reported in every period. This suggests that non-operating items or accounting adjustments are obscuring the underlying reality that the business is currently unable to generate cash from its primary activities.
As reported in the quarterly cash flow statements, YDES has consistently generated negative free cash flow, with quarterly outflows ranging from $21.6K to $688.4K, indicating that the company remains in a cash-burning phase with no clear path to self-sustaining operations in the near term.
The lack of positive free cash flow is a critical concern given the company's limited cash reserves. Investors should monitor whether the company can reach a commercial inflection point before its current liquidity is exhausted by these ongoing operational deficits.
Based on the reported figures, YDES has utilized significant capital for share repurchases, including $7.4M in 2025Q1 and $3.1M in 2024Q2, which appears highly unusual for a clinical-stage biotech firm that is simultaneously reporting substantial operating losses and maintaining a very limited cash balance.
The decision to prioritize share buybacks while the core business is burning cash suggests a potential misalignment in capital allocation strategy. This deployment of capital may have unnecessarily accelerated the depletion of the company's liquidity, leaving it in a more vulnerable position for future financing needs.
As indicated by the quarterly cash flow data, YDES has experienced erratic working capital movements, with changes ranging from a $423.1K inflow in 2024Q1 to a $197.3K outflow in 2023Q4, reflecting the inherent instability of managing cash cycles in a pre-commercial, research-heavy diagnostic business model.
These fluctuations suggest that the company's cash position is highly sensitive to the timing of payables and receivables, which are likely tied to irregular clinical trial milestones. Such volatility complicates cash flow forecasting and underscores the difficulty of maintaining stable liquidity in the current operating environment.
Quick answers to the most common questions about buying YDES stock.
YD Bio Limited Ordinary Shares (YDES) generated $-1.8M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
YD Bio Limited Ordinary Shares (YDES) reported negative free cash flow of $4.7M in 2024, indicating capital requirements exceeded cash from operations.
YD Bio Limited Ordinary Shares (YDES) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.